Structural Formula (Aeeeee8e 8f0a 4e87 Ba2a B617223889f0 01)
Lamivudine
Product Images NDC 64330-001
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Lamivudine (NDC 64330-001). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Centaur Pharmaceuticals Private Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image (Aeeeee8e 8f0a 4e87 Ba2a B617223889f0 02)
This text appears to be a table or graph showing the effectiveness of Lamivudine in treating HIV-1 in patients. It includes dosages of 150mg and 500mg and tracks the proportion of patients with HIV-1 RNA below a certain level over time. However, without further context or a clear visual representation of the data, it is difficult to provide a more detailed description or analysis.*
Container Label (Aeeeee8e 8f0a 4e87 Ba2a B617223889f0 03)
This is a description of a medication called Lamivudine, in tablet form with a strength of 150 mg. The tablets are manufactured by Centaur Pharmaceuticals and the package contains 60 tablets. The recommended usual dosage is not provided and requires prescribing information. The tablets should be stored between 20°-25°C (66°-77°F) and may be stored between 15°-30°C (59°-86°F) for a short period of time. The medication is to be dispensed in a child-resistant container as defined by the USP. A barcode and NDC number are also included.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
